Skip to content
Menu

Amphastar Pharmaceuticals, Inc. AMPH

Full chart Compare
Set alert

Price alert · AMPH

All alert types
28.11 USD -1.60 (-5.39%)

Regular-session close

28.11 0.00 0.00%

After hours · Nov 19, 4:01 PM ET

27.95 Day range 29.56
16.65 52-week range 31.00
YTD
+4.97%
1 year
+10.80%

5D -1.03 (-3.53%)

282930FriMonTueWedThu28.11
Market cap
1.20B
Revenue (ttm)
745.79M
Profit margin
13.27%
EPS (ttm)
2.18
Shares out
42.65M
P/E ratio
12.89
Forward P/E
8.38
YTD return
+4.97%
1-year return
+10.80%
50-day average
26.33
Volume
662.51K
Avg volume
468.40K
Open
29.36
Previous close
29.71
Day's range
27.95 – 29.56
52-week range
16.65 – 31.00
Beta
0.94
Analysts
Hold
Price target
24.50 (-12.8%)
Earnings date
Feb 25, 2027

Key statistics

200-day average
22.38
Enterprise value
1.73B
Price / sales
1.61
Price / book
1.47
Revenue growth
8.20%
Free cash flow
9.20M
Total cash
230.63M
Total debt
691.69M
Return on equity
12.44%
Short % of float
21.71%

Fundamental scorecard

15 of 25 checks passed on AMPH’s reported financials

ValueGrowthProfitabilityHealthDividend

15of 25 checks passed

  • Value 5 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
AMPH Revenue — quarterly 207.61M
AMPH Net income — quarterly 37.76M
AMPH EPS — quarterly 0.89

Earnings

AMPH recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 20260.787———
Nov 5, 2026Sep 30, 20260.8591.14+0.28+32.71%
Aug 6, 2026Jun 30, 20260.620.91+0.29+46.77%
May 7, 2026Mar 31, 20260.700.42-0.28-40.00%
Feb 26, 2026Dec 31, 20250.9030.73-0.17-19.16%
Nov 6, 2025Sep 30, 20250.770.93+0.16+20.78%

Upgrades / downgrades

AMPH analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026Wells FargomainEqual-WeightEqual-Weight
Aug 18, 2026BarclaysmainEqual-WeightEqual-Weight
Aug 7, 2026Piper SandlermainNeutralNeutral
Aug 7, 2026Wells FargomainEqual-WeightEqual-Weight
Jun 29, 2026B of A SecuritiesdownNeutralUnderperform
Jun 3, 2026BarclaysmainEqual-WeightEqual-Weight

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States

News

Your note

Sign in to keep a note on AMPH — it syncs with the Stock Master app.

Insider holders

AMPH insider holders
InsiderRelationLatest transactionDateShares held
DEFLIN GAYLEDirectorStock Award(Grant)May 31, 202619,057
GERST DIANE G.DirectorStock Award(Grant)May 31, 202631,899
LEE HOWARD SDirectorStock Award(Grant)May 31, 2026159,350
LIAWATIDEWI YAKOBOfficer and DirectorStock Award(Grant)Mar 8, 2026125,384
PETERS WILLIAM JChief Financial OfficerConversion of Exercise of derivative securityNov 15, 2026167,076
PETERSEN FLOYD FDirectorSaleDec 11, 202571,368

Institution ownership

AMPH institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.00%5,118,737143.89MSep 29, 2026
Dimensional Fund Advisors LP5.59%2,382,99166.99MSep 29, 2026
State Street Corporation3.92%1,674,06047.06MSep 29, 2026
American Century Companies Inc3.72%1,585,06844.56MSep 29, 2026
Vanguard Capital Management LLC2.91%1,239,34734.84MSep 29, 2026
Marshall Wace LLP2.85%1,216,25334.19MSep 29, 2026

Fund ownership

AMPH fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF4.39%1,873,13352.65MSep 29, 2026
American Century ETF Trust-Avantis U.S. Small Cap Value ETF3.06%1,303,43536.64MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.48%1,055,67629.68MJun 29, 2026
Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund2.12%902,73725.38MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.97%839,36623.59MSep 29, 2026
DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio1.40%596,07716.76MJul 30, 2026